Tech Firm Partners to Advance AI-Powered Support for MDs
Source: Streetwise Reports  (12/11/25)
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why. More >

Clean Tech Co.'s 'Forever Chemicals' Solution Featured in Industry Magazine
Source: Streetwise Reports  (12/8/25)
BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term. More >

AI-Powered Healthcare Co. Gains Traction as US Expansion Accelerates
Source: John Newell  (12/8/25)
John Newell of John Newell & Associates shares why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy. More >

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe  (12/4/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report. More >

AI Breakthroughs Drive New Momentum in Oncology Research
Source: Streetwise Reports  (12/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences. More >

Water Treatment Firm Finds High-Performance Solution for $2.99B PFAS Market
Source: Streetwise Reports  (12/3/25)
Chemical Engineering magazine features BioLargo Inc. (OTCQX:BLGO) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) for its advancements in electrostatic PFAS treatment technology. Read why one expert likes this stock long-term. More >

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'
Source: Dr. Douglas Loe  (12/2/25)
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report. More >

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive
Source: Streetwise Reports  (12/1/25)
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma. More >

Biotech Co.'s Q3/25 Progress on Lead Programs Steady
Source: Patrick Trucchio  (12/1/25)
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report. More >

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain
Source: Streetwise Reports  (11/26/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers. More >

Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
Source: Streetwise Reports  (11/19/25)
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally. More >

US$12 Billion RNA Deal Triggers Sector Shakeup
Source: Streetwise Reports  (11/14/25)
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026. More >

Preclinical Compounds Perform Better Than Existing Drugs
Source: Dr. Douglas Loe  (11/13/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report. More >

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Source: Streetwise Reports  (11/13/25)
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward. More >

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Source: Streetwise Reports  (11/12/25)
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management. More >

Clean Tech Finds Massive Energy Savings in PFAS Treatment
Source: Streetwise Reports  (11/5/25)
BioLargo Inc. (BLGO:OTCQX) announces a significant upgrade to its patented Aqueous Electrostatic Concentrator (AEC) system, reducing energy consumption by over 90% in large-scale "forever chemical" treatment for drinking water. More >

Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter  (10/30/25)
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report. More >

2 Key Catalysts Ahead for Developer of Psych Drugs
Source: Patrick Trucchio  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report. More >

Co. Speeds Up Development of New Drug for Depression
Source: Andrew Tsai  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. More >

Price Target on Psychiatric Drug Biotech Boosted 200%
Source: Dr. Laura Chico  (10/27/25)
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. More >

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan  (10/24/25)
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. More >

Chen's High-Grade Gold, Silver Plays for Q4
Source: Streetwise Reports  (10/23/25)
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside? More >

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Source: Streetwise Reports  (10/20/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases. More >

Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Source: Streetwise Reports  (10/17/25)
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization." More >

Biopharma's New MASH Drug Has Two MOAs
Source: Patrick Trucchio  (10/15/25)
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report. More >